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Introduction: A substantial, national need exists for culturally acceptable, accessible opioid use disorder (OUD)
treatment. Medication for opioid use disorder (MOUD) is regarded as effective in treating OUD; however,
retention in MOUD programs remains low nationally. One known barrier to MOUD retention is stigma, partic
ularly within ethno-racial minority communities. Peer recovery specialists (PRSs), individuals with shared
experience in substance use and recovery, may be particularly well suited to support patients in MOUD treat
ment, and may have capacity to play a key role in decreasing stigma-related barriers to MOUD retention.
Methods: This study used qualitative methods to solicit feedback on how patients receiving methadone treatment
(MT) experience stigma (i.e., toward substance use [SU] and MT). Study staff also gathered information
regarding how a PRS role may reduce stigma and improve retention in care, including barriers and facilitators to
the PRS role shifting stigma. Study staff conducted semi-structured qualitative interviews and focus groups (N =
32) with staff and patients receiving MT at an opioid treatment program as well as PRSs in Baltimore.
Results: Participants identified experiences of internalized, as well as enacted and anticipated, MT and SU stigma,
and described these as barriers to treatment. Participants also identified opportunities for PRSs to shift stigmarelated barriers for patients receiving MT through unique aspects of the PRS role, such as their shared lived
experience.
Conclusions: Reducing stigma surrounding SUD and MT is critical for improving MOUD outcomes, and future
research may consider how the PRS role can support this effort.

1. Introduction
An estimated 1.6 million Americans currently live with opioid use
disorder (OUD; Substance Abuse and Mental Health Services Adminis
tration, 2020). The fatality rate attributed to overdoses continues to
increase during the COVID-19 pandemic—estimated opioid overdose
exceeded 100,000 between April 2020 and April 2021, a staggering
~29% increase from the previous year (CDC, 2021). Opioid-related fa
tality rates continue to rise among ethno-racial minority populations
(Wilson, 2020; James and Jordan, 2018). Recent studies found a 40%
increase in opioid overdose rates among Black populations compared to
White counterparts between 2018 and 2019 (Larochelle et al., 2021).
Overall increases in recent opioid overdose deaths have been greater in

Black and African American communities (Khatri et al., 2021; Patel
et al., 2021).
A clear and substantial need exists for accessible, culturally aligned
treatment for OUD, particularly for historically underserved, ethnoracial minority populations. Federally approved medications for
opioid use disorder (MOUD), including methadone treatment (MT) and
buprenorphine, are efficacious for treating OUD (Mattick et al., 2009,
2014). However, retention is a persistent challenge in MOUD programs,
with six-month retention rates below 50% nationally (Morgan et al.,
2018; Williams et al., 2017; Williams et al., 2019). Further, low-income,
ethno-racial minorities are at the highest risk of treatment dropout
(Manhapra et al., 2017; Samples et al., 2018; Stahler & Mennis, 2018;
Weinstein et al., 2017).
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Stigma—or the devaluation and discrediting associated with a per
sonal attribute, mark, or characteristic such as race, ethnicity, or sexual
minority orientation (Goffman, 2009)—is a barrier to OUD treatment
access and retention. Stigma surrounds both substance use disorder
(SUD) more broadly (Hammarlund et al., 2018; Van Boekel et al., 2013)
and MOUD specifically (Earnshaw et al., 2013; Madden, 2019). Stigmarelated barriers to MOUD retention are particularly salient for ethnoracial minority communities (Brener et al., 2010; Hammarlund et al.,
2018; Jones et al., 2015), where substance use has been further stig
matized and compounded by historically racist U.S. drug policies (Hart
& Hart, 2019; Kunins, 2020).
Theoretical frameworks of stigma conceptualize stigma as occurring
through three mechanisms: internalized, enacted, and anticipated
(Earnshaw & Chaudoir, 2009). Internalized stigma refers to the degree
to which someone endorses negative beliefs and feelings toward them
selves, enacted stigma is one's perceived experiences of discrimination,
and anticipated stigma is the degree to which people expect to experi
ence stigma/discrimination in the future (Earnshaw & Chaudoir, 2009).
Stigma exists at multiple levels, including the individual (Earnshaw
et al., 2013; Hammarlund et al., 2018), provider, organizational, and
societal levels (Madden, 2019; Van Boekel et al., 2013). SUD and MOUD
stigmas at each of these levels and mechanisms contribute to poor OUD
outcomes and poor retention in OUD care (Earnshaw et al., 2013;
Hammarlund et al., 2018; Madden, 2019; Van Boekel et al., 2013).
Further, current stigma literature argues that researchers must
examine stigmatized identities from an intersectional approach, as they
do not exist in isolation but rather operate at multiple levels to shape
individuals' experiences and health experiences (Williams & Fredrick,
2015). Stigmatized identities cannot easily be unraveled from one
another and typically have an interdependent relationship (Turan et al.,
2019; Williams & Fredrick, 2015). Thus, we must acknowledge that
stigmas experienced by racial/ethnic minority individuals with OUD
cannot be considered in isolation. Compounding internalized, enacted,
and anticipated SUD and MOUD stigmas, low-income, minority in
dividuals with OUD face numerous other health comorbidities, which
are also often stigmatized (i.e., mental health, infectious diseaserelated), and may also experience race/ethnicity-related stigma and
discrimination (Zerger et al., 2014). We must consider how multiple
types of health- and race-related stigmas further diminish treatment
outcomes for low-income, minority individuals with OUD, particularly
in the context of the devastating health disparities of COVID-19 (Gold
et al., 2020). Therefore, an urgent need exists to develop and evaluate
innovative strategies to reduce stigma at these multiple levels among
low-income, ethno-racial minority individuals to improve engagement
in care.
Peer recovery specialists (PRSs), individuals with lived substance use
and recovery experience, bring their shared experiences into their in
teractions with clients and thus may have the capacity to play a unique
role in reducing stigma. Various studies have speculated that PRS
engagement has decreased client SUD stigma within both their samples
and communities (e.g., Haberle et al., 2014; Walsh et al., 2008); how
ever, studies directly measuring these effects among people with SUD
are sparse. To our knowledge, only one study published to-date reported
a decrease in patient internalized substance use stigma following PRS
engagement (Vayshenker et al., 2016). While studies examining the
effect of PRS contact on client experiences of both SUD and MOUD
stigma have been limited to-date, PRS models may reduce stigma by
sharing their lived experience, and thus normalizing the experience of
living with an SUD and being in recovery (ASTHO, 2020). Further, PRS
engagement may buffer or protect individuals from the negative impacts
of enacted stigma, based on social support theory (Vaux, 1988). PRSs
may also have the potential to reduce stigma around different forms of
treatment, such as MOUD, especially if MOUD was part of the PRS's own
path to recovery. Unfortunately, however, PRSs may also perpetuate
stigma if they view MOUD as a less appropriate path to recovery.
Evaluating the impact that PRSs could feasibly play in the mitigation (or

perpetuation) of multiple levels of stigma, and the downstream effects
this may have on patient-level treatment outcomes, including retention
in OUD care, is essential.
The current study aimed to understand: (1) how stigma manifests at
multiple levels (including internalized MT and SUD stigma, as well as
enacted and anticipated MT and SUD stigma) among predominantly
low-income, ethno-racial minority individuals in MT from various per
spectives (patient, staff and PRS); and (2) how a PRS role may reduce
stigma and improve retention in OUD care, including barriers and fa
cilitators to the PRS role in shifting stigma.
2. Methods
2.1. Setting
The study team conducted this study as part of a larger parent study
[NCT04248933] that was adapting and piloting a PRS-delivered
behavioral intervention to support successful MT outcomes. This study
took place at the University of Maryland Drug Treatment Center
(UMDTC), a community-based, outpatient substance use treatment
center in West Baltimore which provides MOUD, including MT. Study
staff collected data between September 2019 and March 2020 and
conducted analysis from December 2020 to January 2021.
2.2. Participants
Participants for this study (N = 32) included patients currently
enrolled in MT at UMDTC (n = 20), as well as providers, staff, and PRSs
(n = 12). A majority of participants identified as male and Black or
African American (see Table 1 for demographic data and patient char
acteristics). UMDTC staff participants (n = 8) included drug treatment
counselors, case managers, nurses, and physicians, and PRSs (n = 4)
were working in community and SUD treatment settings in Baltimore.
2.3. Procedures
We purposively sampled UMDTC staff based on their roles in patient
care and program administration. We recruited PRSs working in SUD
treatment and community settings in Baltimore City through networking
with a PRS research collaborator and community-based organizations.
We recruited patients receiving MT at UMDTC via flyers and word of
Table 1
Participant demographics and other characteristics.

Race
Black or African American
White
Other
Gender
Male
Female
Mean age (SD)
Highest level of education
Some high school
High school diploma or
GED
Some college
Associate's degree
Bachelor's degree
Master's degree or higher
Average years working in SU
treatment (SD)
Disclosed SU history

Patient
participants
(n = 20)

Staff
participants
(n = 7)

PRS
participants
(n = 5)

n (%)

n (%)

n (%)

12 (60.0)
6 (30.0)
2 (10.0)

5 (71.4)
1 (14.3)
1 (14.3)

4 (75.0)
1 (25.0)

14 (70.0)
6 (30.0)
48.4 (10.0)

4 (57.1)
3 (42.9)
52.4 (11.9)

1 (25.0)
4 (75.0)
44.6 (7.8)

7 (35.0)
8 (40.0)

0 (0.0)
1 (14.3)

0 (0.0)
2 (40.0)

3 (15.0)
2 (10.0)
0 (0.0)
0 (0.0)
–

0 (0.0)
2 (28.6)
1 (14.3)
3 (42.6)
11.1 (9.0)

1 (20.0)
1 (20.0)
1 (20.0)
0 (0.0)
7.5 (5.1)

–

5 (71.4)

5 (100.0)

SU = substance use; PRS = peer recovery specialist.
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mouth, as well as referrals by treatment program staff who identified
patients who were both struggling and consistent with MT adherence to
receive feedback from both perspectives.
The study gave all participants the option of participating in focus
groups (n = 22) or individual interviews (n = 10) to accommodate
varying work schedules and personal preference given the sensitive
nature of the proposed topics, which was in alignment with stakeholder
feedback. The study audio recorded interviews and focus groups; all
participants provided informed consent, which included permission for
audio recording. Participants chose to participate in a focus group or
individual interview, but could not participate in both. Patients only
participated in focus groups with other patients, and staff and PRSs
participated in focus groups together. Four focus groups took place with
a maximum of six participants each. The study provided all participants
a $25 gift card compensation for their participation.
The University of Maryland, College Park IRB reviewed and
approved all study procedures, with an Authorization Agreement (IAA)
approved by the University of Maryland, Baltimore.

PRS may reduce stigma and improve retention in care through qualities
unique to the PRS role, as well as through PRS actions/behaviors (Aim
2). However, participants noted that the PRS having a different recovery
pathway may contribute to stigma experienced by the patient, which
could in turn act as a barrier to a PRS reducing stigma and improving
retention in care (Aim 2).
3.1. Aim 1: how stigma manifests among individuals in methadone
treatment from patient, staff, and PRS perspectives
3.1.1. Internalized SUD and MT stigma
Patient participants described their experiences of internalized
stigma surrounding both their own SUD and receiving MT treat
ment—both of which acted as barriers to successful treatment outcomes.
Patients shared negative views of themselves as a result of their sub
stance use. For instance, one patient participant reflected on his belief
that, due to his substance use history, he had “ruined” his brain and
“[will] never fix it, which is pretty sad.” Patients described feeling
abnormal as a result of their substance use and that they hoped to be
“normal” through receiving treatment.
In addition to negative views about oneself as a result of their SUD,
patients also shared negative attitudes toward themselves regarding use
of MT. For instance, one patient stated that he felt that it “sucks that a
guy like me needs that [methadone].” Another patient shared the feeling
that taking methadone meant that he was still using drugs:

2.4. Qualitative analysis
Local key stakeholders, including a PRS on our team, informed
interview guide adaptation, which was iteratively adapted throughout
the study based on feedback from participants. Study staff transcribed
and de-identified all recordings and reviewed them for accuracy. For this
analysis, we focused on how stigma manifests at multiple levels and
feedback on how a PRS could shift stigma. Using thematic analysis, the
coding team iteratively developed a codebook outlining themes, sub
themes, and definitions in the transcripts and modified the codebook as
new concepts arose (Boyatzis, 1998). The coding team used rapid
qualitative analysis methods, modeled after Gale et al. (2019) who
observed consistent findings among traditional, in-depth, and rapid
analysis. One coder initially reviewed and coded each transcript for
stigma-related themes. Then, a second member of the study team coded
each excerpt from the first round at the node-level. A third, a doctoral
student arbiter, reviewed all codes. The coding team met weekly to
discuss findings and resolve questions and discrepancies.

So, I just went from one drug to the other drug and then the methadone
itself is a drug. They tell me it's a pain reliever, or blocker. What is it
blocking?
– [Patient Participant, Black, mid-50s]
Providers and staff also shared a perspective that acknowledged
internalized MT stigma among their patients. For instance, one provider
shared how they could see societal stigma toward MT internalized in
their patients:
It's the stigma of society…I've had some client[s] that was bouncing back
into society. You look at this person, you would never know they got high.
But in their mind, they always felt less than … people would plant the seed
that if you're on prescribed medication, you still getting high…it's the
stigma that has to be broken.

3. Results
Several themes emerged from the patient, staff, and PRS interviews
and focus groups, following our two primary study aims: (1) to under
stand how MT and SUD stigmas manifest among low-income, minority
individuals in MT at multiple levels through enacted, internalized, and
anticipated stigma mechanisms; and (2) to understand if/how a PRS role
may reduce stigma and improve retention in care, including barriers and
facilitators to the PRS role in shifting stigma. Participants described
internalized and enacted MT and SUD stigma at the patient, organiza
tional, and societal levels (see Fig. 1) as barriers to reaching successful
treatment outcomes (Aim 1). Participants expressed that working with a

– [PRS Participant, Black, early 60s]
Other staff members echoed this sentiment, stating that some of their
patients “worry that they won't be accepted and wonder if they're,
especially when it comes to the self-help groups, whether they're still
really clean.”
3.1.2. Enacted and anticipated stigmas
Participants described enacted and anticipated stigmas, for both SUD

Fig. 1. Identified levels of stigma.
Note. aIndicates SUD stigma, bIndicates MOUD stigma.
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and MT, at multiple levels, including at the patient level, provider/staff
level, within institutions (e.g., the treatment center), and broader soci
etal, political and cultural levels.

Speaking of stigma, we once had a mayor that got on television and said
everybody who's noddin down the market is on methadone. The leader of
our city, uninformed people who's watching her on television…Guess what
their perception is now? And it's totally wrong. That's miseducation…
that's what this is all about to me.

3.1.2.1. Patient-level enacted SUD/MT stigma. Patient participants on an
abstinence-based recovery pathway perpetuated stigmatizing views to
ward other patients who received MT services while remaining in active
use. One such patient participant described other patients who still use
as “their willpower not being strong enough,” and not caring to get well.
Other participants described their belief that patients on MT who are
still in active use only use MT as a “gate shot” (i.e., using MT to avoid
withdrawal-related illness), and that this was an inappropriate use of
MT.

– [Staff Participant, Black, early-50s]
3.2. Aim 2: perspectives on how a PRS could shift stigma
3.2.1. Peer qualities that could impact stigma
Staff and patient participants described potential qualities in a PRS
that may shift multiple forms of stigma, including shared experience,
particularly when the peer and patient have similar paths to recovery,
and specific peer behaviors that could support shifting stigma.

3.1.2.2. Provider/staff-level enacted SUD/MT stigma. Patients and staff
described stigmas perpetuated by staff and through policies at the
treatment center. One patient described feeling as though they were
being nitpicked and labeled as “incompliant,” due to loitering and
parking issues, which made it hard for them to move forward in treat
ment. Multiple patient participants discussed experiences with one
counselor who continuously referred to patients as “junkies.”

3.2.1.1. Shared experience: normalization. The shared experience be
tween PRS and patient may normalize the MT and SUD experience and
can give the peer credibility such that they will not make a patient feel
judged:
Having a peer, there's just a certain level of credibility that's already
there… being somebody with whom he could speak without necessarily
being judged. And I think that that's another key thing about peers; is that I
think there's this inherent understanding that there really isn't room for
that it's a judgment free zone.

3.1.2.3. Familial-level enacted MT stigma. Patient participants described
that their families' stigmatizing views toward their engagement in MT
was a barrier to treatment/reaching their goals. One patient participant
described their family encouraging them to discontinue treatment due to
their negative attitude toward MT:

– [Staff Participant, White, late-20s]

I was staying with my daughter. I was going through a whole lot of stuff.
And, my daughter, she wanted me to get off methadone, and she said it
wasn't a good idea and, you know, and I was doing it, you know, just
because I was just hearing her voice.

One patient highlighted that a peer may be able to connect to the
patient in ways that the counselor cannot due to having that shared
experience:
My counselor … she's never actually walked in my shoes. That's always, to
me, always better when you have someone that's been there, that you can
relate to on a deeper level when it comes to addiction because there's so
many facets to this thing and it's not just one, it's not black and white. So, I
think that would be a good thing … a peer probably could reach the client
in places that a counselor may not

– [Patient participant, White, mid-30s]
3.1.2.4. Community-level enacted stigmas. Participants described stig
mas toward low socio-economic status, racial/ethnic minority status,
MT, and SUD as existing at the general society level and within the
government (i.e., officials holding stigmatizing views). Further explan
ing the stigma toward MT, one staff participant described an unfair
image being painted of patients:

– [Patient Participant, Black, early-50s]
3.2.2. Peer actions/behaviors
Staff and patient participants described how the peer could poten
tially impact stigma at multiple levels.

It's not a real image of what methadone and that's what only thing that
people zoom in on. They zoom in on the negatives of the city where there's
so much positive good stuff that goes on. They zoom in on the person you
see noddin' but in reality, the person that's sitting beside you at that job
may also be on methadone. You just don't know about that. So, you're
only seeing part of it.

3.2.2.1. Supporting clients and other treatment team members. Peers can
support patients by creating healthy relationships with them and
creating open spaces where patients can disclose information safely due
to lack of judgment. Many of the patients do not have safe spaces like
this outside of the clinic; thus, having peers who support them in this
way may keep them engaged in treatment:

– [Staff Participant, Black, early-50s]
Another staff participant described how these various stigmas com
pound one another, creating an overwhelming experience for patients to
handle:

I think having healthy relationships which many people do not have
outside of here is one piece that keeps them coming back. They feel safe
here, they're able to come and even disclose information that they may not
disclose anywhere else because, you know, speak openly and feel safe in
doing so.

There just so, so many layers of stigma that can be attached to basically
being a poor person of color in Baltimore City with a heroin addiction.
And if you add, you know, trauma, you know, suffering any kind of
violence or exposure to violence, you know, on top of that, it's a lot for any
one person to handle.

– [Staff Participant, Black, early-50s]

– [Staff Participant, White, late 20s]

3.2.2.2. Dispel myths and stigma. Many patients may come into MT with
very little information on what to expect, or with misunderstandings of
or myths surrounding MT. Staff participants described an opportunity
for patients to receive quality information from peers once they come
into treatment and, thus, reduce miseducation, stigma, and confusion:

One participant also identified the role of government officials in
contributing to misinformation as a factor in perpetuating MT stigma
within Baltimore City:

4
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It's about education first and helping them relate to what's going on.
Because they just don't understand and what they do understand, they
don't understand. And they've got to understand information. And that's
confusion. That's confusion right there.

substance substitution. Similarly, participants described feeling as
though they were still perceived by community members as being in
active addiction due to receiving MT.
The experiences of MT and SUD stigma that participants in this study
described are similar to the levels of stigma reported in qualitative
studies with predominately White samples, including at the societal
level (Browne et al., 2016) and institutional level (e.g., health care
systems; Murney et al., 2020), and how these stigmas act as barriers to
entering and/or staying in MT. Nonetheless, these stigmas are also more
pervasive when coupled with ethnoracial discrimination and cultural
misunderstandings. Racial discrimination by health care providers is
more commonly experienced by people who receive MT vs. other MOUD
(Pro & Zaller, 2020). Furthermore, MT is often portrayed using images
of Black individuals who use heroin and are involved in criminal
behavior, which creates challenges related to engagement and retention
for people experiencing multiple sources of marginalization (Goedel
et al., 2020). Indeed, when understanding how MT and SUD stigmas
affect MT/SUD treatment experiences among racial-ethnic minority
populations, an intersectional lens helps to take into account the various
other forms of discrimination and health care discrepancies that these
populations face. Further, more work needs to be done to understand
other factors that may impact the effects of SUD and MOUD stigmas on
treatment outcomes, such as frequency of discriminative/stigmatizing
experiences, and the degree of internalization following stigmatizing
experiences.
Working with a PRS may increase accessibility to SUD treatment
services in underserved, low-income, minority populations, while also
reducing the stigma-related barriers that participants in this study
identified. Participants revealed that PRS-shared experience with sub
stance use and recovery may act to normalize and destigmatize sub
stance use, thus, shifting patient internalized stigma, particularly when
aligned on shared recovery pathways. Moreover, participants described
that, through having an interventionist who is in long-term recovery
themselves, they would be able to look to this person as inspiration for
steps they may take in their own life. Of note, participants also described
that integrating PRSs into treatment centers may shift organizational
stigma toward SUD, which has been reported as a barrier to treatment
(Van Boekel et al., 2013), through modeling what persons in long-term
recovery may contribute to the workplace. Evaluating the effects of PRS
interventions on stigma at these multiple levels is an important area of
future research. Further, future research should aim to understand the
limitations of PRS interventions for shifting stigma, and in what sce
narios other intervention strategies may be necessary, such as in
addressing other systemic factors at organizational and societal levels.
This study takes a step toward gathering key stakeholder perspec
tives on stigma as a barrier to MT retention and how a PRS may support
shifting stigma. With feedback that working with a PRS is perceived as
having the capabilities to destigmatize substance use and MOUD care
among clients in an MT program, this qualitative study has informed
data collection for our ongoing work to evaluate a PRS-delivered
behavioral activation (BA) intervention [NCT04248933]. Given that
qualities unique to the PRS role, such as shared-experience, are
perceived to be a key component of PRS interventions, additional work
is needed to incorporate assessment of self-disclosures and clinical
competency as part of evaluating the PRS role (Kohrt et al., 2015).
Further, future research should continue to specify aspects of the PRS
role that may affect stigma-related outcomes and other patient-level
outcomes, such as intervention/treatment retention, including both
barriers and facilitators.
Future work should also gather additional stakeholder perspectives
regarding the intersection between SUD and MT stigmas with other
health-related stigmas and racial/ethnic discrimination. Though spar
ingly, participants described how these stigmas compound one another,
similar to the syndemic effects that other barriers to MT have on one
another (Kleinman et al., 2020). Yet a stronger focus on the intersection
of SUD and MT stigmas with racial/ethnic discrimination is sorely

– [Staff Participant, Black, early-50s]
3.2.2.3. Shift organizational stigma. Having peers working within the
context of MT treatment programs may help in shifting the stigma that
exists within the organization itself by seeing someone in recovery
contribute to the organization. Further, peers directly support staff,
which may help to alleviate stigma toward people in recovery, and in
turn, the staff aid the peers by giving them responsibilities that benefit
the organization:
It reduces stigma within the organization because now clinicians,
regardless of their own internal bias, are seeing that people with lived
experience are benefiting to the organization, which creates opportunity
for the clients to have a beneficial contribution.
– [PRS Participant, White, early-30s]
3.2.3. Barriers to PRSs shifting stigma
One patient participant noted that there may be “differences in re
covery paths” between the peers and the patients. These differences
could cause the patient to feel that the peer is “looking down on [them]”
and could potentially cause the patient to “close right up like a book” or
be less open during sessions. Indeed, patients and PRSs having different
recovery pathways may amplify stigma and be a barrier to how a PRS
may provide supportive, nonjudgmental services.
4. Discussion
The overall aim of this study was to understand how stigmas mani
fest at multiple levels among low-income, minority individuals in MT
and to gather feedback on how a PRS role may impact stigma. Findings
highlight how MT and SUD stigmas exist at multiple levels and serve as
barriers to reaching successful MT outcomes. Participants described
both internalized and enacted MT and SUD stigmas, and their roles in
hindering patients' recovery progress. Participants shared that PRSs may
be able to shift stigma and remove barriers to treatment through their
shared experience. Participants identified various qualities and acts/
behaviors that may help reduce stigma among patients, and potential
barriers when the PRS and client have different pathways to recovery.
Findings suggest that future work should continue to explore how PRSintegration in treatment teams can decrease organizational stigma.
SUD and MT stigma exist at multiple levels, including internalized
within the self, among providers, and patients' communities and fam
ilies. These results are in line with previous qualitative research that
identified enacted and anticipated stigma against SUD and MT from
friends and family, coworkers and employers, and health care workers
(Earnshaw et al., 2013), as well as stigma toward MT, wherein patients
receiving MT treatment are stigmatized as still using drugs (Madden,
2019). This study also highlights patient internalized SUD and MT
stigma, and how these stigmas may act as barriers to patients' treatment
goals. Previous research has examined whether enacted and internalized
SUD stigma predict treatment behaviors (Brener et al., 2010; Hammar
lund et al., 2018) and has found that perceptions of discrimination
predicted treatment dropout, as well as mixed findings on whether
stigma influences treatment seeking. However, little research has
examined how these barriers continue to persist throughout treatment to
affect retention in MT care. Participants in this study described their
perception that MT stigma followed them throughout their treatment
experience; some patient participants described feeling as though they
were still using drugs due to the conceptualization of MT as just a
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needed. The interview guide in this study did not probe on inter
sectionality specifically, which is an important immediate future di
rection of this work. To understand how to adapt a PRS intervention to
shift MT and SUD stigma and promote retention in care, these multiple
intersecting stigmas must be considered together.
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4.1. Limitations
These results should be considered within the context of study lim
itations. While themes surrounding stigma emerged from qualitative
interviews, this was a secondary analysis of a larger study focused on
adapting BA for PRS delivery and barriers to MT retention. Additionally,
we acknowledge that subjectivity exists in the definition of stigma; thus,
what coders identified as stigma may differ from what patients feel as
stigmatizing, which may also differ on a case-by-case basis. Coders'
personal backgrounds may have affected what they defined as stigma
tizing and influenced their coding. However, weekly meetings focused
on resolving discrepancies and discussing perceptions to be as aligned as
possible in what constituted stigma. While this framework informed our
analysis, future research that uses the Stigma Mechanisms Framework
(Earnshaw & Chaudoir, 2009) to design qualitative and quantitative
assessment measures will be essential to further delineate anticipated
and enacted stigmas. Finally, the study recruited study participants from
a single treatment center in Baltimore and all received MT, which may
impact generalizability.
4.2. Conclusions
Improving our understanding of the experiences of SUD and MOUD
stigma within ethnoracial minority communities and identifying acces
sible intervention strategies using peer supports is critically important
for improving engagement in care and care experiences for this popu
lation. Stigmas around SUD, OUD, and MT exist at multiple levels, which
may act as barriers to engaging in and remaining adherent to MT.
Moreover, results suggest that working with a PRS may offer a unique
opportunity to shift stigma through normalization of SUD, modeling
long-term recovery, as well as educating and supporting clients. How
ever, a risk exists of peer stigmatization of clients who have different
recovery pathways; future research should explore the importance of
PRSs and their clients sharing recovery pathways and impacts on
treatment outcomes. Future work is needed to rigorously evaluate how a
PRS intervention can shift stigma at multiple levels.
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